copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
CLINICAL TRIAL NCT06561685 - UChicago Medicine The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents
A Phase 1 Study of LY4050784 in People With Advanced Solid Tumors Researchers want to find the best dose of LY4050784 to treat advanced solid tumors The people in this study have cancer that cannot be cured with standard therapies Their tumors also have a mutation (change) in the SMARCA4 and or BRG1 genes, which play a role in cancer growth LY4050784 targets cancer cells that make a gene called SMARCA2 BRM
Trial | NCT06561685 Trial | NCT06561685 Report issue Study Overview Title A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors Official Title An Open-label, Multicenter Study of LY4050784, a Selective SMARCA2 BRM Inhibitor, in Advanced Solid Tumor Malignancies With SMARCA4 BRG1 Alterations Snapshot Phase Phase 1 Lead Sponsor Eli Lilly